

Facility Name:	
Patient Name:	DOB:
Standing Order Administration of Pneumococcal Conjugate Vaccine (Pneu-C) in Adults <i>*Pharmacy Use Only*</i>	Date:
	Vaccine Products ⁽¹⁾ and Cost Per Dose: • Prevnar 20 (Pneu-C-20): _____ • Capvaxive (Pneu-C-21): _____
Purpose	The Canadian National Advisory Committee on Immunization (NACI) strongly recommends either Pneu-C-20 or Pneu-C-21 vaccination for residents of nursing homes and other chronic care facilities ⁽²⁾ to reduce morbidity and mortality from Invasive Pneumococcal Disease (IPD).
What is Pneumococcal Disease?	Pneumococcal disease is defined as any infection caused by the bacteria S. Pneumoniae. Infections can present as ear and sinus infections, pneumonia, to a more serious condition called invasive pneumococcal disease (IPD). This occurs when the bacteria enter the blood, or the central nervous system, causing sepsis, and meningitis. Invasive disease is more common in older adults, and the incidence increases with age and number of medical conditions. All Individuals who live in long-term care facilities typically experience sustained high IPD rates ⁽³⁾ .
Vaccine Effectiveness	Vaccination is safe and effective at preventing invasive pneumococcal disease (IPD) which can lead to hospitalization and death ^(4,5) .
Route of Administration	Intramuscular injection of 0.5 mL. No booster is currently recommended, but that may change over time.
Timing of Administration	Eligible adults should receive one dose of either Pneu-C-20 or Pneu-C-21 regardless of pneumococcal vaccination history of Pneu-C-13, Pneu-C-15, or Pneu-P-23. Vaccination can be administered at any time of the year.
Based on the information above, I would like to: ☐ Receive a Pneumococcal Conjugate Vaccination Consent Form and discuss the Pneumococcal Conjugate Vaccination in more detail with my Clinical Consultant Pharmacist (CCP) beforehand. ☐ Refuse the Pneumococcal Conjugate Vaccine	
Resident and/or POA Name	
Signature	

1. NACI recommends either Pneu-C-20 or Pneu-C-21 for LTC residents as safe and effective options for preventing IPD and complications. The community pharmacy will supply the product available on the day of administration*
2. Summary of NACI statement of November 15, 2024: Recommendations on the use of pneumococcal vaccines in adults, including PNEU-C-21 <https://www.canada.ca/en/public-health/services/publications/vaccines-immunization/national-advisory-committee-immunization-summary-recommendations-use-pneumococcal-vaccines-adults-pneu-c-21.html>
3. "Residents of Healthcare institutions" <https://www.canada.ca/en/public-health/services/publications/healthy-living/canadian-immunization-guide-part-4-active-vaccines/page-16-pneumococcal-vaccine.html#a17>
4. Prevnar 20 Product Monograph - https://pdf.hres.ca/dpd_pm/00065729.PDF
5. Capvaxive Product Monograph - https://www.merck.ca/en/wp-content/uploads/sites/20/2024/07/CAPVAXIVE-PM_E.pdf